WO2006113647A2 - Recovery of tissue function following administration of b cells to injured tissue - Google Patents

Recovery of tissue function following administration of b cells to injured tissue Download PDF

Info

Publication number
WO2006113647A2
WO2006113647A2 PCT/US2006/014445 US2006014445W WO2006113647A2 WO 2006113647 A2 WO2006113647 A2 WO 2006113647A2 US 2006014445 W US2006014445 W US 2006014445W WO 2006113647 A2 WO2006113647 A2 WO 2006113647A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
tissue
human
injured tissue
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/014445
Other languages
English (en)
French (fr)
Other versions
WO2006113647A3 (en
Inventor
Mark C. Poznansky
Traci T. Goodchild
Mark T. Ungs
Nicholas A.F. Chronos
Nadine Weich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACTx Inc
Original Assignee
ACTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACTx Inc filed Critical ACTx Inc
Priority to AT06750473T priority Critical patent/ATE537249T1/de
Priority to JP2008507782A priority patent/JP4659092B2/ja
Priority to EP06750473A priority patent/EP1877544B1/en
Publication of WO2006113647A2 publication Critical patent/WO2006113647A2/en
Publication of WO2006113647A3 publication Critical patent/WO2006113647A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Definitions

  • kits include antibodies and materials that are specific for the cell type to be isolated, for example B cells, and may be further specialized for use in the heterogeneous cell mixture obtained from a specific tissue or organ.
  • Materials may include apparatus or reagents useful in separation or preparation such as tubing conduits, separators, filtrators, and containers, incubation apparatus including tissue culture equipment and containers, and chemical or molecular reagents. That is, isolation of B cells from a cell preparation from bone marrow may require the use of an antibody or antibodies specific for the surface antigens on the bone marrow derived B cells.
  • such a kit may include an antibody or antibodies specific for the surface antigens on the bone marrow derived cells to be separated from the desired bone marrow derived B cells.
  • kits may also contain devices for the delivery of the B cells.
  • a variety of devices may be included depending on the targeted delivery site. Intravascular and transcutaneous delivery could be achieved with standard syringes while delivery to the brain, heart and kidney may involve specialized transluminal devices that allow for the infusion or direct injection of cells into or around the targeted organ.
  • An advantage of the present invention is that injured tissue is improved following administration of B cells, resulting in enhanced function and quality of life, and decreased morbidity and mortality.
  • FIG. 2 Primary screen monitoring cardiac contractility following injection of specific populations of bone marrow cells post ischemic injury.
  • Bone marrow was harvested from donor Sprague-Dawley rat femurs and tibias and various cell populations isolated.
  • Six recipient rats underwent ligation of the left anterior descending coronary artery and saline, 1 X 10 6 HSCs, 5 X 10 5 HSCs combined with 5 X 10 5 B cells, or 1 X 10 6 B cells alone were directly injected into the infarcted area. After 2 weeks, the surviving animals (5 to 6 rats) underwent follow-up echocardiography and hemodynamic measurements including cardiac contractility (dP/dT) .
  • dP/dT cardiac contractility
  • Bone marrow cell treatment After ligation of the LAD and confirmation of myocardial infarction, animals received a total of 10 6 cells (except for the one case shown in Figure 2 in which 5 x 10 6 B cells alone were injected) in 4 injections of 20 ul (about 250,000 cells per injection, 12,500 cells per ul) directly into the infarcted region are spaced about 1 mm to 2 mm apart, using a Hamilton syringe with a 27 gauge needle. Injections were performed by the surgeon and done by hand, directly into the myocardium. Control animals received saline. The chest was closed using sterile suture (4-0 Vicryl) and the animal was allowed to recover from the surgical procedure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
PCT/US2006/014445 2005-04-18 2006-04-18 Recovery of tissue function following administration of b cells to injured tissue Ceased WO2006113647A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT06750473T ATE537249T1 (de) 2005-04-18 2006-04-18 Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
JP2008507782A JP4659092B2 (ja) 2005-04-18 2006-04-18 損傷組織へのb細胞投与による組織機能の回復
EP06750473A EP1877544B1 (en) 2005-04-18 2006-04-18 Recovery of tissue function following administration of b cells to injured tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67241605P 2005-04-18 2005-04-18
US60/672,416 2005-04-18

Publications (2)

Publication Number Publication Date
WO2006113647A2 true WO2006113647A2 (en) 2006-10-26
WO2006113647A3 WO2006113647A3 (en) 2007-02-08

Family

ID=37115830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014445 Ceased WO2006113647A2 (en) 2005-04-18 2006-04-18 Recovery of tissue function following administration of b cells to injured tissue

Country Status (5)

Country Link
US (2) US7695712B2 (cg-RX-API-DMAC7.html)
EP (1) EP1877544B1 (cg-RX-API-DMAC7.html)
JP (1) JP4659092B2 (cg-RX-API-DMAC7.html)
AT (1) ATE537249T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006113647A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4659092B2 (ja) * 2005-04-18 2011-03-30 エーシーティーエックス,インコーポレイテッド 損傷組織へのb細胞投与による組織機能の回復
US9220813B2 (en) * 2005-04-18 2015-12-29 Holy Cross Hospital, Inc. Cell therapy for limiting overzealous inflammatory reactions in tissue healing
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
KR101922118B1 (ko) 2012-08-27 2018-11-26 삼성전자주식회사 플렉서블 반도체소자 및 그 제조방법
EP2943206A4 (en) 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
WO2015066076A1 (en) 2013-10-28 2015-05-07 Biocardia, Inc. Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
US9775816B2 (en) 2013-11-07 2017-10-03 The General Hospital Corporation Eluting matrix and uses thereof
CN113677354A (zh) * 2019-01-23 2021-11-19 综合医院公司 B细胞免疫疗法
WO2021211997A1 (en) * 2020-04-16 2021-10-21 The General Hospital Corporation B cell immunomodulatory therapy for acute respiratory distress syndrome
WO2022094284A1 (en) * 2020-10-30 2022-05-05 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
CA2505924A1 (en) 2002-11-13 2004-05-27 Micromet Ag Method for identifying antigen specific b cells
JP4659092B2 (ja) * 2005-04-18 2011-03-30 エーシーティーエックス,インコーポレイテッド 損傷組織へのb細胞投与による組織機能の回復

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1877544A4 *

Also Published As

Publication number Publication date
ATE537249T1 (de) 2011-12-15
US8603463B2 (en) 2013-12-10
US20060263339A1 (en) 2006-11-23
WO2006113647A3 (en) 2007-02-08
EP1877544A2 (en) 2008-01-16
JP2008536930A (ja) 2008-09-11
US20100266561A1 (en) 2010-10-21
EP1877544B1 (en) 2011-12-14
US7695712B2 (en) 2010-04-13
JP4659092B2 (ja) 2011-03-30
EP1877544A4 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
US8603463B2 (en) Recovery of tissue function following administration of B cells to injured tissue
US11123367B2 (en) Combined organ and hematopoietic cells for transplantation tolerance of grafts
JP5705127B2 (ja) 梗塞領域灌流改善組成物および血管損傷修復の方法
Hermann et al. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity
US10478456B2 (en) Pharmaceutical preparation
US20070110732A1 (en) Use of Synovium and Omentum for Tissue Engineering
JP2020105216A (ja) 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2007511206A (ja) 骨髄前駆細胞(BMPs)および/または血液由来血中前駆細胞(BDPs)の心臓血管機能性を診断するためのインビトロでの方法
CN114901806B (zh) 细胞群以及其取得方法
US9220813B2 (en) Cell therapy for limiting overzealous inflammatory reactions in tissue healing
KR20060007475A (ko) 세포면역치료제의 제조를 위한 림프구 장기 보관 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008507782

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006750473

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU